Lineage Cell Therapeutics (LCTX) Other Non-Current Liabilities (2010 - 2026)

Lineage Cell Therapeutics has reported Other Non-Current Liabilities for 17 years, with the latest figure at $34.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 463.27% year-over-year to $34.1 million; the trailing twelve-month figure through Mar 2026 stood at $34.1 million (up 463.27% YoY), and the FY2025 full-year result was $43.9 million, up 612.64% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $34.1 million, down from $43.9 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $45.2 million in Q3 2025, with the low at $1000.0 in Q1 2023.
• Historically, Other Non-Current Liabilities has averaged $12.9 million across 5 years, with a median of $3.0 million in 2022.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities slumped 98.8% — and 2025, when it surged 612.64%.
• Lineage Cell Therapeutics' Other Non-Current Liabilities stood at $2000.0 in 2022, then slumped by 50.0% to $1000.0 in 2023, then jumped by 616000.0% to $6.2 million in 2024, then surged by 612.64% to $43.9 million in 2025, then slipped by 22.24% to $34.1 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $34.1 million (Q1 2026), $43.9 million (Q4 2025), and $45.2 million (Q3 2025), per Business Quant data.